Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

scientific article published on 18 May 2015

Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.00753-15
P932PMC publication ID4505221
P698PubMed publication ID25987639

P50authorJonathan BettsQ57560949
David WarehamQ42749726
P2093author name stringLynette M Phee
Binutha Bharathan
P2860cites workAntibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strainsQ80758580
Combination therapy for carbapenem-resistant Gram-negative bacteriaQ87974612
Acinetobacter baumannii: an emerging opportunistic pathogenQ26830893
Staphylococcus aureus elongation factor G--structure and analysis of a target for fusidic acidQ27664084
Determination of minimum inhibitory concentrationsQ28203149
Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in EuropeQ28477449
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaQ29616084
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceQ29617469
Fusidic acid pharmacology, pharmacokinetics and pharmacodynamicsQ33755492
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureusQ34680589
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii.Q34726120
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumanniiQ35023321
When does 2 plus 2 equal 5? A review of antimicrobial synergy testingQ35036156
The epidemiology and control of Acinetobacter baumannii in health care facilitiesQ36382140
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment optionsQ37150308
Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumanniiQ37544704
Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteriaQ37544860
The antimicrobial activity of fusidic acidQ37906160
Genetic basis of antibiotic resistance in pathogenic Acinetobacter speciesQ37944605
In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysisQ38281370
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteriaQ38287949
Antimicrobial heteroresistance: an emerging field in need of clarity.Q38310639
Efforts to support the development of fusidic acid in the United StatesQ38428027
Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumanniiQ41736250
Genetic basis of resistance to fusidic acid in staphylococci.Q41809069
Colistin heteroresistance in acinetobacter and its association with previous colistin therapyQ41912289
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida speciesQ42171162
In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogensQ42255874
Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure.Q42288837
Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint indexQ43253862
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusQ44852902
In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacinQ46557679
Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumanniiQ46939760
Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock.Q54607698
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectmultiple drug resistanceQ643839
Acinetobacter baumanniiQ3241189
P1104number of pages7
P304page(s)4544-4550
P577publication date2015-05-18
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleColistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections
P478volume59

Reverse relations

cites work (P2860)
Q28550341Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model
Q39629148Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae.
Q30235064Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options
Q38940249Colistin: still a lifesaver for the 21st century?
Q38686596Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections
Q36343547Host defense antimicrobial peptides as antibiotics: design and application strategies
Q42407674In Vitro Activity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant Acinetobacter baumannii Clinical Strains
Q40162514In vitro and In vivo Activity of Theaflavin-Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii
Q36363261Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
Q64266788Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii
Q92302901Rational Combinations of Polymyxins with Other Antibiotics
Q58733403Sulbactam enhances the activity of sitafloxacin against extensively-drug resistant
Q64891508The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents.

Search more.